Godavari Biorefineries Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Godavari Biorefineries Ltd filed with BSE on 13 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Godavari Biorefineries reported Q1 FY27 total income growth of 4.9% year-on-year, with the bio-based chemicals business posting 19.4% revenue growth and 53% EBITDA growth while the integrated sugar, cogeneration and ethanol segment reported a widened EBITDA loss. The company commissioned a 200 kilolitres per day grain-based distillery at Sameerwadi, taking total distillery capacity to 800 kilolitres per day, and is evaluating an additional 160 kilolitres per day fungible capacity. Management also reported progress on drug discovery, having filed a CDSCO application for preliminary efficacy trials of its triple-negative breast cancer molecule and secured patents for an anticancer molecule and branched alcohols process.
Numbers mentioned
Revenue from operations: INR557.9 crores (Q1 FY27)
p. 5
“For Q1 FY27, revenue from operations stood at INR557.9 crores, up by 4.6% year-on-year, while total income stood at INR559.9 crores, representing a growth of 4.9%.”
Ashish Sinha, page 5 of the filed PDF · View the filing
EBITDA: INR2.6 crores (Q1 FY27)
p. 5
“EBITDA stood at INR2.6 crores compared to INR6.5 crores in Q1 FY26, with margin at 0.5% against 1.2% last year.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Bio-based chemicals revenue: INR168.7 crores (Q1 FY27)
p. 5
“The bio-based chemicals business delivered a strong performance with revenue growing 19.4% year-on-year to INR168.7 crores, and EBITDA increasing 53% to INR19.2 crores.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Bio-based chemicals EBITDA margin: 11.4% (Q1 FY27)
p. 5
“EBITDA margin expanded to 11.4% from 8.9%, supported by favorable product mix and the benefits of the debottlenecking initiatives.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Integrated sugar, cogeneration and ethanol segment revenue: INR 377.9 crore (Q1 FY27)
p. 5
“Revenue was INR 377.9 crore compared to INR382.8 crores in Q1 FY26, while EBITDA loss widened to INR14.6 crores from INR4.5 crores.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Consolidated net loss: INR19.3 crores (Q1 FY27)
p. 5
“At the consolidated level, the lower operating profitability along with higher depreciation resulted in a net loss of INR19.3 crores compared to INR16 crores in Q1 FY26.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Closing sugar inventory: 65,000 tons (Q1 FY27 end)
p. 11
“It's about 65,000 tons of sugar.”
Ashish Sinha, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
DME pilot trial results — March 2027
stated firmly by Samir Somaiya
p. 6
“But from a timeline of when we will know how the pilot trials conclude will be by March of 2027.”
Samir Somaiya, page 6 of the filed PDF · View the filing
CDSCO permission for TNBC preliminary trials — end of Q3 FY27
stated conditionally by Samir Somaiya
p. 6
“We are hoping for we get these permissions by the end of this third quarter FY27.”
Samir Somaiya, page 6 of the filed PDF · View the filing
Bio-based chemicals quarterly revenue — INR190 crores · current quarter
stated firmly by Samir Somaiya
p. 9
“we are anticipating in this coming quarter INR190 crores of business”
Samir Somaiya, page 9 of the filed PDF · View the filing
Bio-based chemicals quarterly revenue post-debottlenecking — about INR240 crores per quarter · early next financial year
stated conditionally by Samir Somaiya
p. 10
“we further expect that business to grow to a quarterly business of about INR240 crores per quarter, once we complete the debottlenecking and enter the market”
Samir Somaiya, page 10 of the filed PDF · View the filing
Debottlenecking capex for bio-based chemicals — INR25 crores
stated firmly by Samir Somaiya
p. 5
“We have, therefore, decided to invest a further INR25 crores in debottlenecking our capacity to be able to further meet the growing demand for our bio-based specialty chemical business.”
Samir Somaiya, page 5 of the filed PDF · View the filing
Drug discovery spend to preliminary efficacy — about INR20 crores · next 2 to 3 years
stated firmly by Samir Somaiya
p. 7
“No, our estimate of taking it to preliminary efficacy is about INR20 crores over the next 2 to 3 years.”
Samir Somaiya, page 7 of the filed PDF · View the filing
Debt-equity structure — medium term
stated as an aspiration by Samir Somaiya
p. 13
“We will have better ideas as to the debottlenecking of the grain-based front-end facility as we go along.”
Samir Somaiya, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
DME pilot trials are ongoing with results expected by March 2027; bio-butanol has an MoU with Synthomer and government interest in butanol for fuel security.
Answered by Samir Somaiya
Asked by Santosh Shetty: Update on DME and bio-butanol commercialization roadmap
p. 6
“The pilot trials are progressing well. But from a timeline of when we will know how the pilot trials conclude will be by March of 2027.”
Samir Somaiya, page 6 of the filed PDF · View the filing
Management said existing resources are sufficient for the drug discovery program.
Answered by Samir Somaiya
Asked by Dhananjai Bagrodia: Would the company need more fund-raising for R&D or expansion
p. 7
“So, we do believe that we have the resources for this purpose within the system.”
Samir Somaiya, page 7 of the filed PDF · View the filing
Management cited climate/monsoon risk affecting cane and water availability, though recent weeks had improved conditions, and broader geopolitical volatility.
Answered by Samir Somaiya
Asked by Dhananjai Bagrodia: Any risks the company is foreseeing
p. 8
“We were and we remain very focused on looking at climate effects, because there was a prediction of El Niño.”
Samir Somaiya, page 8 of the filed PDF · View the filing
Management said the margin improvement stems from prior debottlenecking now reaching the market, with further growth expected from a new INR25 crore investment.
Answered by Samir Somaiya
Asked by Soumya: Sustainability of chemical business margin and steady-state potential
p. 10
“We definitely see this as a continuing business and a growth opportunity.”
Samir Somaiya, page 10 of the filed PDF · View the filing
Management indicated debt levels are expected to stay broadly similar with only slight changes.
Answered by Samir Somaiya
Asked by Nimish Verma: How will leverage and finance cost trend with ongoing investments
p. 13
“We are looking at broadly keeping debt levels similar or a margin or a slight change, not major changes in the overall debt-equity structure.”
Samir Somaiya, page 13 of the filed PDF · View the filing
Management said near-term focus is on debottlenecking bio-based chemicals and front-end maize preparation investments, alongside committed drug discovery spend.
Answered by Samir Somaiya
Asked by Pahal Sharma: Capital allocation priorities over the next couple of years
p. 14
“Right now, we are focusing on the debottlenecking of bio-based chemicals, and also on front-end investments for quickly debottlenecking what I will call maize preparation devices.”
Samir Somaiya, page 14 of the filed PDF · View the filing
Risks flagged
Climate effects and El Niño impact on rainfall and dam levels affecting cane supply
p. 8
“We were and we remain very focused on looking at climate effects, because there was a prediction of El Niño.”
Samir Somaiya, page 8 of the filed PDF · View the filing
Global geopolitical volatility affecting energy and raw material markets
p. 8
“Otherwise, you know, the world is in complete volatility.”
Samir Somaiya, page 8 of the filed PDF · View the filing
Elevated inventory carrying cost and higher raw material prices impacting profitability
p. 5
“Profitability was impacted by elevated inventory carrying cost and higher raw material prices.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Challenging feedstock conditions and higher manufacturing costs pressuring sugar and ethanol segment
p. 5
“This was primarily due to challenging feedstock conditions and higher manufacturing cost, although improved sugar realization provided some support.”
Ashish Sinha, page 5 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.